

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single-Use Equipment), Process (Cell Processing, Preservation), Cell type (T-Cells, Stem cells), End User (Biopharma, CROs, CMOs), Region - Global Forecast to 2028

Market Report | 2023-07-27 | 236 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global cell therapy technologies market size is projected to reach USD 7.8 billion by 2028 from USD 4.2 billion in 2023, at a CAGR of 13.3 % during the forecast period. Factors such as increasing government investments in cell-based research, rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, increasing GMP certification for cell therapy production facilities are likely to have positive impact on the market growth.

"The process segment held the dominant share in the cell therapy technologies market"

Based on process, the global cell therapy technologies market is segmented into cell processing, cell preservation, distribution & handling, process monitoring & quality control. The cell processing segment held a dominant share in the market in 2022.

Advancement in cell processing techniques is likely to have positive impact on the growth of the market.

"Biopharmaceutical and biotechnology companies segment accounted for the largest share of the application segment in 2022."

Based on end users, the cell therapy technologies market is segmented into biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes & cell banks. In 2022, the biopharmaceutical and biotechnology companies segment accounted for the largest share of the cell therapy technologies market. The segment held the dominant share in the market owing to various factors such as the emphasis on increase in number of cell therapy manufacturing facilities by key market players and rising investment in research activities of cell therapy.

"Asia Pacific region is likely to grow at a faster pace."

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East and Africa. Asia Pacific region is anticipated to grow at a significant CAGR during the forecast period. The growth of the region is majorly driven by the increasing government investments in cell-based research. The increasing demand for cell therapy instruments and products from China, India, and Japan due to the rising research funding for vaccine development and changing disease profiles supports market growth in the Asia Pacific. Furthermore, increasing incidence of chronic and infectious diseases, the rising geriatric population, and government initiatives for healthcare infrastructural improvements are some of the elements anticipated to account for positive impact on the market growth.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 70%, and Demand Side - 30%
- By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

List of Companies Profiled in the Report:

- Thermo Fisher Scientific, Inc. (US)
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Lonza Group (Switzerland)
- Sartorius AG(Germany)
- Terumo Bct, Inc Corporation (Japan) (Terumo BCT is part of Terumo Corporation)
- Becton, Dickinson & Company (US)
- Fresenius Se & co. KGaA (Germany)
- Avantor Inc (US)
- Bio-Techne (US)
- Corning Incorporated (US)
- Fujifilm Irvine Scientific (Japan)
- Maxcyte Inc. (US)
- Werum Software & Systems AG (Part of Korber AG) (Germany)
- Roosterbio Inc. (US)
- Sirion Biotech GmbH (Germany)
- Trakcel (UK)
- L 7 Informatics Inc. (US)
- Miltenyi Biotech (Germany)
- Steamcell Technologies Inc. (Canada)
- GPI Iberia (Formerly Hemosoft) (Spain)
- CodexThemes (France)
- Organabio LLC. (US)
- Ixcells Biotechnologies (US)
- Wilson Wolf 2019 Manufacturing Corporation (US)

Research Coverage:

This report provides a detailed picture of the cell therapy technologies market. It aims at estimating the size and future growth potential of the market across different segments, such as product, process, cell type, end-user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (Increasing government investments in cell-based research, Rising incidence of chronic and infectious diseases, large no of oncology related cell therapy clinical trials, Increasing GMP certification for cell therapy production facilities), restraints (High cost of cell-based research and low success rate), opportunities (Emergence of iPSC as alternatives to ESCs, Increased focus on personalized medicine, Increasing public-private partnerships for development of cell therapies, Emerging Asian markets), and challenges (Survival for small players and new entrants)are influencing the growth of cell therapy technologies market.

- Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.

- Market Development: Comprehensive information about lucrative markets - the report analyses the Cell therapy technologies market across varied regions.

- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the cell therapy technologies market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), Becton, Dickinson, and Company (US), Lonza Group (Switzerland), Sartorius AG (Germany), and among others in the cell therapy technologies market.

Table of Contents:

1□INTRODUCTION□	33
1.1□STUDY OBJECTIVES□	33
1.2□MARKET DEFINITION□	33
1.2.1□INCLUSIONS AND EXCLUSIONS□	33
1.3□MARKET SCOPE□	34
1.3.1□MARKETS COVERED□	34
1.3.2□YEARS CONSIDERED□	34
1.3.3□CURRENCY CONSIDERED□	35
1.4□RESEARCH LIMITATIONS□	35
1.5□STAKEHOLDERS□	35
1.6□SUMMARY OF CHANGES□	36
1.7□RECESSION IMPACT□	36
2□RESEARCH METHODOLOGY□	37
2.1□RESEARCH DATA□	37
FIGURE 1□RESEARCH DESIGN□	37
2.1.1□SECONDARY DATA□	38
2.1.2□PRIMARY DATA□	39
FIGURE 2□CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES□	39
2.2□MARKET SIZE ESTIMATION□	40
FIGURE 3□CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022□	40
FIGURE 4□MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022□	41
FIGURE 5□ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022□	41
2.2.1□INSIGHTS FROM PRIMARIES□	43
FIGURE 6□MARKET VALIDATION FROM PRIMARY EXPERTS□	43
2.2.2□SEGMENT ASSESSMENT (BY PRODUCT, PROCESS, CELL TYPE, AND END USER)□	43
FIGURE 7□MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH□	43
2.3□GROWTH RATE ASSUMPTIONS□	44

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 8	CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS, 2023-2028	45
FIGURE 9	CELL THERAPY TECHNOLOGIES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES	45
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	46
FIGURE 10	DATA TRIANGULATION METHODOLOGY	46
2.5	STUDY ASSUMPTIONS	47
2.6	RISK ANALYSIS	47
2.7	RECESSION IMPACT ANALYSIS	47
TABLE 1	GLOBAL INFLATION RATE PROJECTIONS, 2024-2028 (% GROWTH)	48
TABLE 2	US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	48
TABLE 3	US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)	48
3	EXECUTIVE SUMMARY	49
FIGURE 11	CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)	49
FIGURE 12	CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)	50
FIGURE 13	CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2023 VS. 2028 (USD MILLION)	50
FIGURE 14	CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	51
FIGURE 15	CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC SNAPSHOT	52
4	PREMIUM INSIGHTS	53
4.1	CELL THERAPY TECHNOLOGIES MARKET OVERVIEW	53
FIGURE 16	INCREASING GOVERNMENT INVESTMENT IN CELL-BASED RESEARCH TO BOOST ADOPTION OF CELL THERAPY TECHNOLOGIES	53
4.2	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY (2022)	54
FIGURE 17	T CELLS ACCOUNTED FOR LARGEST MARKET SHARE IN 2022	54
4.3	CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2023 VS. 2028	54
FIGURE 18	MEDIA, SERA, AND REAGENTS SEGMENT TO DOMINATE MARKET IN 2028	54
4.4	CELL THERAPY TECHNOLOGIES MARKET SHARE, BY END USER, 2022 (USD MILLION)	55
FIGURE 19	BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED MARKET IN 2022	55
4.5	CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES	55
FIGURE 20	ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028	55
5	MARKET OVERVIEW	56
5.1	INTRODUCTION	56
5.2	MARKET DYNAMICS	56
FIGURE 21	CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	56
5.2.1	DRIVERS	57
5.2.1.1	Increasing government investments in cell-based research	57
TABLE 4	NIH FUNDING FOR CELL-BASED RESEARCH, 2019-2022 (USD MILLION)	57
5.2.1.2	Rising incidence of chronic and infectious diseases	58
5.2.1.3	Large number of oncology-related cell therapy clinical trials	58
FIGURE 22	CANCER CELL THERAPY PIPELINE, 2021-2022	59
5.2.1.4	Increasing GMP certifications for cell therapy production facilities	59
TABLE 5	EXAMPLES OF MANUFACTURING CERTIFICATIONS AND APPROVALS FOR GMP	59
5.2.2	RESTRAINTS	60
5.2.2.1	High cost of cell-based research and low success rate	60
TABLE 6	COST OF CELL THERAPY EQUIPMENT	60
5.2.3	OPPORTUNITIES	60
5.2.3.1	Emergence of iPSCs as alternatives to ESCs	60
5.2.3.2	Increased focus on personalized medicine	61

5.2.3.3	Increasing partnerships for development of cell therapies	61
5.2.3.4	Emerging Asian markets	62
5.2.4	CHALLENGES	63
5.2.4.1	Survival of small players and new entrants	63
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	63
FIGURE 23	REVENUE SHIFT AND NEW REVENUE POCKETS FOR CELL THERAPY TECHNOLOGIES PROVIDERS	63
5.4	INDICATIVE PRICING MODEL ANALYSIS	63
TABLE 7	PRICING ANALYSIS OF CELL THERAPY PRODUCTS	63
5.5	TECHNOLOGY ANALYSIS	64
5.6	VALUE CHAIN ANALYSIS	64
FIGURE 24	VALUE CHAIN ANALYSIS: RAW MATERIAL AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE	65
5.7	SUPPLY CHAIN ANALYSIS	65
FIGURE 25	CELL THERAPY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS	66
5.8	ECOSYSTEM ANALYSIS OF CELL THERAPY TECHNOLOGIES MARKET	67
FIGURE 26	ECOSYSTEM ANALYSIS	67
TABLE 8	SUPPLY CHAIN ECOSYSTEM	67
5.9	KEY CONFERENCES AND EVENTS IN 2022-2023	68
TABLE 9	CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES AND EVENTS	68
5.10	REGULATORY ANALYSIS	69
5.10.1	REGULATORY LANDSCAPE FOR CELL THERAPIES	69
TABLE 10	NORTH AMERICA: REGULATORY LANDSCAPE FOR CELL THERAPIES	69
TABLE 11	EUROPE: REGULATORY LANDSCAPE FOR CELL THERAPIES	70
TABLE 12	ASIA PACIFIC: REGULATORY LANDSCAPE FOR CELL THERAPIES	70
TABLE 13	ROW: REGULATORY LANDSCAPE FOR CELL THERAPIES	72
5.10.2	LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	73
TABLE 14	NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	73
TABLE 15	EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	74
TABLE 16	ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	74
TABLE 17	LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	75
TABLE 18	MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	75
5.11	PORTER'S FIVE FORCES ANALYSIS	76
TABLE 19	CELL THERAPY TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS	76
5.11.1	THREAT OF NEW ENTRANTS	76
5.11.2	THREAT OF SUBSTITUTES	76
5.11.3	BARGAINING POWER OF SUPPLIERS	76
5.11.4	BARGAINING POWER OF BUYERS	76
5.11.5	DEGREE OF COMPETITION	76
5.12	PATENT ANALYSIS	77
FIGURE 27	PATENT APPLICATIONS FOR CELL THERAPY TECHNOLOGIES, JULY 2013-JULY 2023	77
TABLE 20	CELL THERAPY TECHNOLOGIES MARKET: INDICATIVE LIST OF PATENTS	78
5.13	KEY STAKEHOLDERS AND BUYING CRITERIA	79
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	79
FIGURE 28	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CELL THERAPY PRODUCTS	79
5.13.2	BUYING CRITERIA FOR CELL THERAPY PRODUCTS	80
FIGURE 29	KEY BUYING CRITERIA FOR END USERS	80
6	CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT	81
6.1	INTRODUCTION	82

TABLE 21	CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	82
6.2	MEDIA, SERA, AND REAGENTS	82
6.2.1	IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET	82
TABLE 22	MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)	83
TABLE 23	NORTH AMERICA: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	83
TABLE 24	EUROPE: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	84
TABLE 25	ASIA PACIFIC: MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	84
6.3	CELL ENGINEERING PRODUCTS	85
6.3.1	AVAILABILITY OF VARIOUS CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH	85
TABLE 26	CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY	85
TABLE 27	CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)	85
TABLE 28	NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	86
TABLE 29	EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	86
TABLE 30	ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	86
6.4	CELL CULTURE VESSELS	87
6.4.1	WIDE USAGE OF CELL CULTURE VESSELS IN CELL GROWTH APPLICATIONS	87
TABLE 31	CELL CULTURE VESSELS MARKET, BY REGION, 2021-2028 (USD MILLION)	87
TABLE 32	NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	87
TABLE 33	EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	88
TABLE 34	ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	88
6.5	CELL THERAPY EQUIPMENT	88
TABLE 35	CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	89
TABLE 36	CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)	89
TABLE 37	NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, 2021-2028 (USD MILLION)	90
TABLE 38	EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	90
TABLE 39	ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	90
6.5.1	CELL PROCESSING EQUIPMENT	91
6.5.1.1	Cell processing equipment to dominate market	91
TABLE 40	CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)	91
TABLE 41	NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	92
TABLE 42	EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	92
TABLE 43	ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	92
6.5.2	SINGLE-USE EQUIPMENT	93
6.5.2.1	Benefits of single-use equipment to ensure end-user demand	93
TABLE 44	SINGLE-USE EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)	93
TABLE 45	NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	93
TABLE 46	EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	94
TABLE 47	ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	94
6.5.3	OTHER EQUIPMENT	94
TABLE 48	OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2021-2028 (USD MILLION)	95
TABLE 49	NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	95
TABLE 50	EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	95
TABLE 51	ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	96
6.6	SYSTEMS & SOFTWARE	96
6.6.1	NEED TO MONITOR DIFFERENT STAGES OF CELL PROCESSING TO DRIVE DEMAND	96
TABLE 52	SYSTEMS & SOFTWARE MARKET, BY REGION, 2021-2028 (USD MILLION)	97
TABLE 53	NORTH AMERICA: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	97

TABLE 54	EUROPE: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	97
TABLE 55	ASIA PACIFIC: SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	98
6.7	OTHER PRODUCTS	98
TABLE 56	OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2021-2028 (USD MILLION)	98
TABLE 57	NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	99
TABLE 58	EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	99
TABLE 59	ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	99
7	CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS	100
7.1	INTRODUCTION	101
TABLE 60	CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	101
7.2	CELL PROCESSING	101
7.2.1	CELL PROCESSING TO HOLD LARGEST MARKET SHARE TILL 2028	101
TABLE 61	CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2021-2028 (USD MILLION)	102
TABLE 62	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)	102
TABLE 63	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)	103
TABLE 64	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2021-2028 (USD MILLION)	103
7.3	CELL PRESERVATION, DISTRIBUTION, AND HANDLING	103
7.3.1	INCREASING DEMAND FOR CELL-BASED MEDICAL PRODUCTS AND THERAPIES TO DRIVE SEGMENT GROWTH	103
TABLE 65	CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY REGION, 2021-2028 (USD MILLION)	104
TABLE 66	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION)	104
TABLE 67	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION)	105
TABLE 68	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, DISTRIBUTION, AND HANDLING, BY COUNTRY, 2021-2028 (USD MILLION)	105
7.4	PROCESS MONITORING & QUALITY CONTROL	105
7.4.1	NEED TO ENSURE QUALITY AND ACCURACY OF CELL PROCESSING TO BOOST ADOPTION	105
TABLE 69	CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2021-2028 (USD MILLION)	106
TABLE 70	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)	106
TABLE 71	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)	107
TABLE 72	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2021-2028 (USD MILLION)	107
8	CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE	108
8.1	INTRODUCTION	109
TABLE 73	CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	109
8.2	T CELLS	109
8.2.1	RIISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH	109
TABLE 74	CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY REGION, 2021-2028 (USD MILLION)	110
TABLE 75	NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	110
TABLE 76	EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	111
TABLE 77	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR T CELLS, BY COUNTRY, 2021-2028 (USD MILLION)	111

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.3 □STEM CELLS □112

8.3.1 □INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET □112

TABLE 78 □CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY REGION, 2021-2028 (USD MILLION) □112

TABLE 79 □NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □113

TABLE 80 □EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □113

TABLE 81 □ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR STEM CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □113

8.4 □OTHER CELLS □114

TABLE 82 □CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY REGION, 2021-2028 (USD MILLION) □114

TABLE 83 □NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD

MILLION) □114

TABLE 84 □EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □115

TABLE 85 □ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER CELLS, BY COUNTRY, 2021-2028 (USD MILLION) □115

?

9 □CELL THERAPY TECHNOLOGIES MARKET, BY END USER □116

9.1 □INTRODUCTION □117

TABLE 86 □CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) □117

9.2 □BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES □117

9.2.1 □GROWING NUMBER OF CELL THERAPY MANUFACTURING FACILITIES TO DRIVE MARKET □117

TABLE 87 □CELL THERAPY TECHNOLOGIES MARKET & BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) □118

TABLE 88 □NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □118

TABLE 89 □EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □119

TABLE 90 □ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □119

9.3 □CROS & CMOS □119

9.3.1 □FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH □119

TABLE 91 □CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2021-2028 (USD MILLION) □120

TABLE 92 □NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION) □120

TABLE 93 □EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION) □121

TABLE 94 □ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2021-2028 (USD MILLION) □121

9.4 □RESEARCH INSTITUTES & CELL BANKS □121

9.4.1 □RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH □121

TABLE 95 □CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY REGION, 2021-2028 (USD MILLION) □122

TABLE 96 □NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION) □122

TABLE 97 □EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION) □123

TABLE 98 □ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES & CELL BANKS, BY COUNTRY, 2021-2028 (USD MILLION) □123

10 □CELL THERAPY TECHNOLOGIES MARKET, BY REGION □124

10.1 □INTRODUCTION □125

TABLE 99 □CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION) □125

10.2 □NORTH AMERICA □125

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.2.1 NORTH AMERICA: RECESSION IMPACT 125

FIGURE 30 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 126

TABLE 100 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 127

TABLE 101 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 127

TABLE 102 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 127

TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 128

TABLE 104 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 128

TABLE 105 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 128

10.2.2 US 129

10.2.2.1 Increasing R&D activities to support market growth 129

TABLE 106 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 129

TABLE 107 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 129

TABLE 108 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 130

TABLE 109 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 130

TABLE 110 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 130

10.2.3 CANADA 131

10.2.3.1 Increasing government funding to drive adoption of cell therapy instruments 131

TABLE 111 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 131

TABLE 112 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 132

TABLE 113 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 132

TABLE 114 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 132

TABLE 115 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 133

10.3 EUROPE 133

10.3.1 EUROPE: RECESSION IMPACT 133

TABLE 116 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 134

TABLE 117 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 134

TABLE 118 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 135

TABLE 119 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 135

TABLE 120 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 135

TABLE 121 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 136

10.3.2 GERMANY 136

10.3.2.1 Germany to hold largest share of European market 136

TABLE 122 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 137

TABLE 123 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 137

TABLE 124 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 138

TABLE 125 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 138

TABLE 126 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 138

10.3.3 UK 139

10.3.3.1 Favorable funding and investment scenario to drive market 139

TABLE 127 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 139

TABLE 128 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION) 139

TABLE 129 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION) 140

TABLE 130 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION) 140

TABLE 131 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION) 140

10.3.4 FRANCE 141

10.3.4.1 Availability of government and private support to drive market 141

TABLE 132 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION) 141

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 133	FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	141
TABLE 134	FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	142
TABLE 135	FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	142
TABLE 136	FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	142
10.3.5	ITALY	143
10.3.5.1	Initiatives favoring cell and gene therapy development to support market growth	143
TABLE 137	ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	143
TABLE 138	ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	143
TABLE 139	ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	144
TABLE 140	ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	144
TABLE 141	ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	144
10.3.6	SPAIN	145
10.3.6.1	Increasing funding from private and public organizations to aid market growth	145
TABLE 142	SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	145
TABLE 143	SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	145
TABLE 144	SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	146
TABLE 145	SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	146
TABLE 146	SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	146
10.3.7	REST OF EUROPE	147
TABLE 147	REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	147
TABLE 148	REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	147
TABLE 149	REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	148
TABLE 150	REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	148
TABLE 151	REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	148
10.4	ASIA PACIFIC	149
FIGURE 31	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT	149
10.4.1	ASIA PACIFIC: RECESSION IMPACT	150
TABLE 152	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	150
TABLE 153	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	151
TABLE 154	ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	151
TABLE 155	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	152
TABLE 156	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	152
TABLE 157	ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	152
10.4.2	CHINA	153
10.4.2.1	Increasing cell therapy-based trials to support market growth	153
TABLE 158	CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	153
TABLE 159	CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	154
TABLE 160	CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	154
TABLE 161	CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	154
TABLE 162	CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	155
10.4.3	JAPAN	155
10.4.3.1	Rising geriatric population and growing disease prevalence to drive market	155
TABLE 163	JAPAN: CANCER INCIDENCE IN MALES VS FEMALES, BY TYPE, 2022	156
TABLE 164	JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	156
TABLE 165	JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	157
TABLE 166	JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	157
TABLE 167	JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	157

TABLE 168	JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	158
10.4.4	INDIA	158
10.4.4.1	Favorable government regulations to support market growth	158
TABLE 169	INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	159
TABLE 170	INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	159
TABLE 171	INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	160
TABLE 172	INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	160
TABLE 173	INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	160
10.4.5	REST OF ASIA PACIFIC	161
TABLE 174	REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	161
TABLE 175	REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	161
TABLE 176	REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	162
TABLE 177	REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	162
TABLE 178	REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	162
10.5	LATIN AMERICA	163
10.5.1	AVAILABILITY OF GRANTS FOR CELL-BASED RESEARCH TO DRIVE MARKET	163
10.5.2	LATIN AMERICA: RECESSION IMPACT	163
TABLE 179	LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	164
TABLE 180	LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	164
TABLE 181	LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	165
TABLE 182	LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	165
TABLE 183	LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	165
10.6	MIDDLE EAST & AFRICA	166
10.6.1	INCREASING R&D FUNDING FOR STEM CELL THERAPY TO DRIVE MARKET	166
10.6.2	MIDDLE EAST & AFRICA: RECESSION IMPACT	166
TABLE 184	MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2021-2028 (USD MILLION)	167
TABLE 185	MIDDLE EAST & AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2021-2028 (USD MILLION)	167
TABLE 186	MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2021-2028 (USD MILLION)	168
TABLE 187	MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2021-2028 (USD MILLION)	168
TABLE 188	MIDDLE EAST & AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2021-2028 (USD MILLION)	168
11	COMPETITIVE LANDSCAPE	169
11.1	INTRODUCTION	169
11.2	STRATEGIES ADOPTED BY KEY PLAYERS	170
FIGURE 32	CELL THERAPY TECHNOLOGIES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS	170
11.3	REVENUE SHARE ANALYSIS	171
FIGURE 33	REVENUE ANALYSIS OF KEY PLAYERS, 2020-2022	171
11.4	MARKET SHARE ANALYSIS	171
FIGURE 34	CELL THERAPY TECHNOLOGIES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022	172
TABLE 189	CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION	172
11.5	COMPANY EVALUATION MATRIX, 2022	173
11.5.1	STARS	174
11.5.2	EMERGING LEADERS	174
11.5.3	PERVASIVE PLAYERS	174
11.5.4	PARTICIPANTS	174
FIGURE 35	CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022	175
11.6	COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS	176
11.6.1	COMPANY PRODUCT FOOTPRINT (25 COMPANIES)	176

TABLE 190	PRODUCT FOOTPRINT ANALYSIS: KEY PLAYERS	176
11.6.2	COMPANY PROCESS FOOTPRINT (25 COMPANIES)	177
TABLE 191	PROCESS FOOTPRINT ANALYSIS: KEY PLAYERS	177
11.6.3	COMPANY REGIONAL FOOTPRINT (25 COMPANIES)	178
TABLE 192	REGIONAL FOOTPRINT ANALYSIS: KEY PLAYERS	178
11.7	COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022	179
11.7.1	PROGRESSIVE COMPANIES	179
11.7.2	STARTING BLOCKS	179
11.7.3	RESPONSIVE COMPANIES	179
11.7.4	DYNAMIC COMPANIES	179
FIGURE 36	CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022	180
11.8	COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS	181
TABLE 193	CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS	181
TABLE 194	CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SME PLAYERS	182
11.9	COMPETITIVE SCENARIO AND TRENDS	183
11.9.1	PRODUCT LAUNCHES	183
TABLE 195	CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2020-APRIL 2023	183
11.9.2	DEALS	184
TABLE 196	CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2020-APRIL 2023	184
11.9.3	OTHER DEVELOPMENTS	185
TABLE 197	CELL THERAPY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS, JANUARY 2020-APRIL 2023	185
12	COMPANY PROFILES	186
12.1	KEY MARKET PLAYERS	186
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*		
12.1.1	THERMO FISHER SCIENTIFIC, INC.	186
TABLE 198	THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW	186
FIGURE 37	THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)	187
12.1.2	MERCK KGAA	191
TABLE 199	MERCK KGAA: BUSINESS OVERVIEW	191
FIGURE 38	MERCK KGAA: COMPANY SNAPSHOT (2022)	192
12.1.3	DANAHER CORPORATION	195
TABLE 200	DANAHER CORPORATION: BUSINESS OVERVIEW	195
FIGURE 39	DANAHER CORPORATION: COMPANY SNAPSHOT (2022)	196
12.1.4	LONZA GROUP	200
TABLE 201	LONZA GROUP: BUSINESS OVERVIEW	200
FIGURE 40	LONZA GROUP: COMPANY SNAPSHOT (2022)	201
12.1.5	SARTORIUS AG	203
TABLE 202	SARTORIUS AG: BUSINESS OVERVIEW	203
FIGURE 41	SARTORIUS AG: COMPANY SNAPSHOT (2022)	204
12.1.6	TERUMO BCT, INC.	206
TABLE 203	TERUMO BCT, INC: BUSINESS OVERVIEW	206
FIGURE 42	TERUMO BCT, INC.: COMPANY SNAPSHOT (2022)	207
12.1.7	BECTON DICKINSON AND COMPANY	209
TABLE 204	BECTON DICKINSON AND COMPANY: BUSINESS OVERVIEW	209
FIGURE 43	BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)	210
12.1.8	FRESENIUS SE & CO. KGAA	212

TABLE 205	FRESENIUS SE & CO. KGAA: BUSINESS OVERVIEW	212
FIGURE 44	FRESENIUS SE & CO: COMPANY SNAPSHOT (2022)	213
12.1.9	AVANTOR, INC.	215
TABLE 206	AVANTOR, INC.: BUSINESS OVERVIEW	215
FIGURE 45	AVANTOR, INC.: COMPANY SNAPSHOT (2022)	215
12.1.10	BIO-TECHNE	218
TABLE 207	BIO-TECHNE: BUSINESS OVERVIEW	218
FIGURE 46	BIO-TECHNE: COMPANY SNAPSHOT (2022)	219
12.1.11	CORNING INCORPORATED	221
TABLE 208	CORNING INCORPORATED: BUSINESS OVERVIEW	221
FIGURE 47	CORNING INCORPORATED: COMPANY SNAPSHOT (2022)	222
12.1.12	FUJIFILM IRVINE SCIENTIFIC	223
TABLE 209	FUJIFILM IRVINE SCIENTIFIC: BUSINESS OVERVIEW	223
FIGURE 48	FUJIFILM IRVINE SCIENTIFIC: COMPANY SNAPSHOT (2022)	224
12.1.13	MAXCYTE, INC.	226
TABLE 210	MAXCYTE, INC.: BUSINESS OVERVIEW	226
FIGURE 49	MAXCYTE, INC.: COMPANY SNAPSHOT (2022)	226
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.		
12.2	OTHER PLAYERS	228
12.2.1	WERUM IT SOLUTIONS	228
12.2.2	ROOSTERBIO, INC.	229
12.2.3	SIRION BIOTECH	230
12.2.4	TRAKCEL	230
12.2.5	L7 INFORMATICS, INC.	231
12.2.6	MILTENYI BIOTEC B.V. & CO. KG	231
12.2.7	STEMCELL TECHNOLOGIES	233
12.2.8	GPI IBERIA (FORMERLY HEMASOFT)	234
12.2.9	MAK-SYSTEM	235
12.2.10	ORGANABIO	235
12.2.11	IXCELLS BIOTECHNOLOGIES	236
12.2.12	WILSON WOLF	236
?		
13	APPENDIX	237
13.1	DISCUSSION GUIDE	237
13.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	241
13.3	CUSTOMIZATION OPTIONS	243
13.4	RELATED REPORTS	243
13.5	AUTHOR DETAILS	244

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single-Use Equipment), Process (Cell Processing, Preservation), Cell type (T-Cells, Stem cells), End User (Biopharma, CROs, CMOs), Region - Global Forecast to 2028

Market Report | 2023-07-27 | 236 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature